Ph 2, Double-Masked, Randomized, Parallel, Sham Surgery/Placebo Control, Multi-Center Study to Evaluate Systemic IMT Regimens as Graft Rejection Prophylaxis Following Transplantation of hESC Derived RPE Cells in Patients With AMD

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
Indications Dry age-related macular degeneration
Focus Adverse reactions
Acronyms PORTRAY
Sponsors Astellas Institute for Regenerative Medicine

Most Recent Events

25 Jul 2017 Planned End Date changed from 1 May 2019 to 5 May 2019.
25 Jul 2017 Planned primary completion date changed from 1 May 2017 to 5 May 2017.
25 Jul 2017 Status changed from discontinued to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight